-
1
-
-
41949119102
-
Paclitaxel and docetaxel resistance: Molecular mechanisms and development of new generation taxanes
-
Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem 2(7), 920-942 (2007).
-
(2007)
Chem Med Chem
, vol.2
, Issue.7
, pp. 920-942
-
-
Galletti, E.1
Magnani, M.2
Renzulli, M.L.3
Botta, M.4
-
2
-
-
84872288933
-
Update on taxane development: New analogs and new formulations
-
Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des. Devel. Ther. 6, 371-384 (2012).
-
(2012)
Drug Des. Devel. Ther.
, vol.6
, pp. 371-384
-
-
Yared, J.A.1
Tkaczuk, K.H.2
-
3
-
-
0034880214
-
Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation
-
Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13), 1590-1598 (2001).
-
(2001)
Eur. J. Cancer
, vol.37
, Issue.13
, pp. 1590-1598
-
-
Gelderblom, H.1
Verweij, J.2
Nooter, K.3
Sparreboom, A.4
-
4
-
-
68949199436
-
The adaptation of lipid nanocapsule formulations for blood administration in animals
-
Hureaux J, Lagarce F, Gagnadoux F, Clavreul A, Benoit JP, Urban T. The adaptation of lipid nanocapsule formulations for blood administration in animals. Int. J. Pharm 379(2), 266-269 (2009).
-
(2009)
Int. J. Pharm
, vol.379
, Issue.2
, pp. 266-269
-
-
Hureaux, J.1
Lagarce, F.2
Gagnadoux, F.3
Clavreul, A.4
Benoit, J.P.5
Urban, T.6
-
5
-
-
33745386420
-
Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules
-
Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23(6), 1243-1250 (2006).
-
(2006)
Pharm. Res.
, vol.23
, Issue.6
, pp. 1243-1250
-
-
Peltier, S.1
Oger, J.M.2
Lagarce, F.3
Couet, W.4
Benoit, J.P.5
-
6
-
-
84881182067
-
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide
-
Saliou B, Thomas O, Lautram N et al. Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide. Eur. J. Pharm. Sci. 50(2), 172-180 (2013).
-
(2013)
Eur. J. Pharm. Sci.
, vol.50
, Issue.2
, pp. 172-180
-
-
Saliou, B.1
Thomas, O.2
Lautram, N.3
-
7
-
-
84865282526
-
Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride
-
Vrignaud S, Hureaux J, Wack S, Benoit J-P, Saulnier P. Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride. Int. J. Pharm. 436(1-2), 194-200 (2012).
-
(2012)
Int. J. Pharm.
, vol.436
, Issue.1-2
, pp. 194-200
-
-
Vrignaud, S.1
Hureaux, J.2
Wack, S.3
Benoit, J.-P.4
Saulnier, P.5
-
8
-
-
78751705543
-
Tumor transfection after systemic injection of DNA lipid nanocapsules
-
Morille M, Passirani C, Dufort S et al. Tumor transfection after systemic injection of DNA lipid nanocapsules. Biomaterials 32(9), 2327-2333 (2011).
-
(2011)
Biomaterials
, vol.32
, Issue.9
, pp. 2327-2333
-
-
Morille, M.1
Passirani, C.2
Dufort, S.3
-
9
-
-
84884156153
-
EGFR siRNA lipid nanocapsules effciently transfect glioma cells in vitro
-
Resnier P, David S, Lautram N et al. EGFR siRNA lipid nanocapsules effciently transfect glioma cells in vitro. Int. J. Pharm. 454(2), 748-755 (2013).
-
(2013)
Int. J. Pharm.
, vol.454
, Issue.2
, pp. 748-755
-
-
Resnier, P.1
David, S.2
Lautram, N.3
-
10
-
-
77949274490
-
Toxicological study and effcacy of blank and paclitaxel-loaded lipid nanocapsules after i.V. Administration in mice
-
Hureaux J, Lagarce F, Gagnadoux F et al. Toxicological study and effcacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice. Pharm. Res. 27(3), 421-430 (2010).
-
(2010)
Pharm. Res.
, vol.27
, Issue.3
, pp. 421-430
-
-
Hureaux, J.1
Lagarce, F.2
Gagnadoux, F.3
-
11
-
-
68949218775
-
The gastrointestinal stability of lipid nanocapsules
-
Roger E, Lagarce F, Benoit JP. The gastrointestinal stability of lipid nanocapsules. Int. J. Pharm. 379(2), 260-265 (2009).
-
(2009)
Int. J. Pharm.
, vol.379
, Issue.2
, pp. 260-265
-
-
Roger, E.1
Lagarce, F.2
Benoit, J.P.3
-
12
-
-
84887371418
-
Fate of Paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery
-
Groo a-C, Saulnier P, Gimel J-C et al. Fate of Paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int. J. Nanomed. 8(1), 4291-4302 (2013).
-
(2013)
Int. J. Nanomed.
, vol.8
, Issue.1
, pp. 4291-4302
-
-
Groo, A.-C.1
Saulnier, P.2
Gimel, J.-C.3
-
13
-
-
70350617685
-
Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis
-
Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control. Release 140(2), 174-181 (2009).
-
(2009)
J. Control. Release
, vol.140
, Issue.2
, pp. 174-181
-
-
Roger, E.1
Lagarce, F.2
Garcion, E.3
Benoit, J.P.4
-
14
-
-
33748313404
-
A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats
-
Garcion E, Lamprecht A, Heurtault B et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 5(7), 1710-1722 (2006).
-
(2006)
Mol. Cancer Ther.
, vol.5
, Issue.7
, pp. 1710-1722
-
-
Garcion, E.1
Lamprecht, A.2
Heurtault, B.3
-
15
-
-
12644278301
-
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
-
Sparreboom A, Van Asperen J, Mayer U et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl Acad. Sci. USA 94(5), 2031-2035 (1997).
-
(1997)
Proc. Natl Acad. Sci. USA
, vol.94
, Issue.5
, pp. 2031-2035
-
-
Sparreboom, A.1
Van Asperen, J.2
Mayer, U.3
-
16
-
-
77953917000
-
Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells
-
Roger E, Lagarce F, Garcion E, Benoit JP. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur. J. Pharm. Sci. 40(5), 422-429 (2010).
-
(2010)
Eur. J. Pharm. Sci.
, vol.40
, Issue.5
, pp. 422-429
-
-
Roger, E.1
Lagarce, F.2
Garcion, E.3
Benoit, J.P.4
-
17
-
-
0036297426
-
A novel phase inversion-based process for the preparation of lipid nanocarriers
-
Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 19(6), 875-880 (2002).
-
(2002)
Pharm Res.
, vol.19
, Issue.6
, pp. 875-880
-
-
Heurtault, B.1
Saulnier, P.2
Pech, B.3
Proust, J.E.4
Benoit, J.P.5
-
18
-
-
70350244685
-
PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat
-
Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MNVR. PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm. Res. 26(11), 2495-2503 (2009).
-
(2009)
Pharm. Res.
, vol.26
, Issue.11
, pp. 2495-2503
-
-
Bhardwaj, V.1
Ankola, D.D.2
Gupta, S.C.3
Schneider, M.4
Lehr, C.M.5
Kumar, M.N.V.R.6
-
19
-
-
77953360626
-
Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles
-
Agueros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J. Control. Release 145(1), 2-8 (2010).
-
(2010)
J. Control. Release
, vol.145
, Issue.1
, pp. 2-8
-
-
Agueros, M.1
Zabaleta, V.2
Espuelas, S.3
Campanero, M.A.4
Irache, J.M.5
-
20
-
-
77955294499
-
Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats
-
Jin J, Bi H, Hu J et al. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. Biopharm. Drug Dispos. 31(4), 264-268 (2010).
-
(2010)
Biopharm. Drug Dispos.
, vol.31
, Issue.4
, pp. 264-268
-
-
Jin, J.1
Bi, H.2
Hu, J.3
-
21
-
-
79955522520
-
The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles
-
Mo R, Jin X, Li N et al. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials 32(20), 4609-4620 (2011).
-
(2011)
Biomaterials
, vol.32
, Issue.20
, pp. 4609-4620
-
-
Mo, R.1
Jin, X.2
Li, N.3
-
22
-
-
78349308871
-
Development and in vivo evaluation of an oral drug delivery system for paclitaxel
-
Iqbal J, Sarti F, Perera G, Bernkop-Schnürch A. Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials 32(1), 170-175 (2011).
-
(2011)
Biomaterials
, vol.32
, Issue.1
, pp. 170-175
-
-
Iqbal, J.1
Sarti, F.2
Perera, G.3
Bernkop-Schnürch, A.4
-
23
-
-
1242337284
-
Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors
-
Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res. 21(2), 261-270 (2004).
-
(2004)
Pharm. Res.
, vol.21
, Issue.2
, pp. 261-270
-
-
Yang, S.1
Gursoy, R.N.2
Lambert, G.3
Benita, S.4
-
24
-
-
84883582500
-
Enhanced oral delivery of paclitaxel using acetylcysteine functionalized chitosan-vitamin e succinate nanomicelles based on a mucus bioadhesion and penetration mechanism
-
Lian H, Zhang T, Sun J et al. Enhanced oral delivery of paclitaxel using acetylcysteine functionalized chitosan-vitamin E succinate nanomicelles based on a mucus bioadhesion and penetration mechanism. Mol. Pharm. 10 (9), 3447-3458 (2013).
-
(2013)
Mol. Pharm.
, vol.10
, Issue.9
, pp. 3447-3458
-
-
Lian, H.1
Zhang, T.2
Sun, J.3
-
25
-
-
84896724791
-
Enhanced oral bioavailability of paclitaxel by concomitant use of absorption enhancers and P-glycoprotein inhibitors in rats
-
Montaseri H, Mohammadi-Samani S, Zarea B, Sobhani Z, Ahmadi F. Enhanced oral bioavailability of paclitaxel by concomitant use of absorption enhancers and P-glycoprotein inhibitors in rats. J. Chemother. 25(6), 355-361 (2013).
-
(2013)
J. Chemother.
, vol.25
, Issue.6
, pp. 355-361
-
-
Montaseri, H.1
Mohammadi-Samani, S.2
Zarea, B.3
Sobhani, Z.4
Ahmadi, F.5
-
26
-
-
11144240987
-
The effect of verapamil on the pharmacokinetics of paclitaxel in rats
-
Choi JS, Li X. The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24(1), 95-100 (2005).
-
(2005)
Eur. J. Pharm. Sci.
, vol.24
, Issue.1
, pp. 95-100
-
-
Choi, J.S.1
Li, X.2
-
27
-
-
84880079471
-
Carboxymethyl-chitosan-tethered lipid vesicles: Hybrid nanoblanket for oral delivery of paclitaxel
-
Joshi N, Saha R, Shanmugam T, Balakrishnan B, More P, Banerjee R. Carboxymethyl-chitosan-tethered lipid vesicles: hybrid nanoblanket for oral delivery of paclitaxel. Biomacromolecules 14(7), 2272-2282 (2013).
-
(2013)
Biomacromolecules
, vol.14
, Issue.7
, pp. 2272-2282
-
-
Joshi, N.1
Saha, R.2
Shanmugam, T.3
Balakrishnan, B.4
More, P.5
Banerjee, R.6
-
28
-
-
84864013044
-
Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel
-
Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 33(28), 6758-6768 (2012).
-
(2012)
Biomaterials
, vol.33
, Issue.28
, pp. 6758-6768
-
-
Jain, S.1
Kumar, D.2
Swarnakar, N.K.3
Thanki, K.4
-
29
-
-
84863783683
-
Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study
-
Zabaleta V, Ponchel G, Salman H, Agueros M, Vauthier C, Irache JM. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur. J. Pharm. Biopharm. 81(3), 514-523 (2012).
-
(2012)
Eur. J. Pharm. Biopharm.
, vol.81
, Issue.3
, pp. 514-523
-
-
Zabaleta, V.1
Ponchel, G.2
Salman, H.3
Agueros, M.4
Vauthier, C.5
Irache, J.M.6
-
30
-
-
77952996831
-
Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats
-
Lee CK, Choi JS. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology 85(6), 350-356 (2010).
-
(2010)
Pharmacology
, vol.85
, Issue.6
, pp. 350-356
-
-
Lee, C.K.1
Choi, J.S.2
-
31
-
-
84855800458
-
Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats
-
Park JH, Hur HJ, Woo JS, Lee HJ. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur. J. Pharm. Sci. 45(3), 296-301 (2012).
-
(2012)
Eur. J. Pharm. Sci.
, vol.45
, Issue.3
, pp. 296-301
-
-
Park, J.H.1
Hur, H.J.2
Woo, J.S.3
Lee, H.J.4
-
32
-
-
40449086665
-
Dose translation from animal to human studies revisited
-
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 22(3), 659-661 (2008).
-
(2008)
FASEB J.
, vol.22
, Issue.3
, pp. 659-661
-
-
Reagan-Shaw, S.1
Nihal, M.2
Ahmad, N.3
-
33
-
-
0036163415
-
Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut
-
Bardelmeijer HA, Ouwehand M, Malingre MM, Schellens J, Beijnen JH, Van Tellingen O. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother. Pharmacol. 49(2), 119-125 (2002).
-
(2002)
Cancer Chemother. Pharmacol.
, vol.49
, Issue.2
, pp. 119-125
-
-
Bardelmeijer, H.A.1
Ouwehand, M.2
Malingre, M.M.3
Schellens, J.4
Beijnen, J.H.5
Van Tellingen, O.6
-
34
-
-
0036554742
-
Infuence of Cremophor El on the bioavailability of intraperitoneal paclitaxel
-
Gelderblom H, Verweij J, Van Zomeren DM et al. Infuence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin. Cancer Res. 8(4), 1237-1241 (2002).
-
(2002)
Clin. Cancer Res.
, vol.8
, Issue.4
, pp. 1237-1241
-
-
Gelderblom, H.1
Verweij, J.2
Van Zomeren, D.M.3
-
35
-
-
0032833650
-
Cremophor EL causes (pseudo-)non-linear pharmacokinetics of paclitaxel in patients
-
Van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-)non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer 81(2), 330-335 (1999).
-
(1999)
Br. J. Cancer
, vol.81
, Issue.2
, pp. 330-335
-
-
Van Tellingen, O.1
Huizing, M.T.2
Panday, V.R.3
Schellens, J.H.4
Nooijen, W.J.5
Beijnen, J.H.6
-
36
-
-
33747415451
-
Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake
-
Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux JC, Benoit JP. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A 78(3), 620-628 (2006).
-
(2006)
J. Biomed. Mater. Res. A
, vol.78
, Issue.3
, pp. 620-628
-
-
Vonarbourg, A.1
Passirani, C.2
Saulnier, P.3
Simard, P.4
Leroux, J.C.5
Benoit, J.P.6
-
37
-
-
33646389800
-
Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors
-
Khalid MN, Simard P, Hoarau D, Dragomir A, Leroux JC. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm. Res. 23(4), 752-758 (2006).
-
(2006)
Pharm. Res.
, vol.23
, Issue.4
, pp. 752-758
-
-
Khalid, M.N.1
Simard, P.2
Hoarau, D.3
Dragomir, A.4
Leroux, J.C.5
-
38
-
-
6344251596
-
Novel long-circulating lipid nanocapsules
-
Hoarau D, Delmas P, David S, Roux E, Leroux JC. Novel long-circulating lipid nanocapsules. Pharm. Res. 21(10), 1783-1789 (2004).
-
(2004)
Pharm. Res.
, vol.21
, Issue.10
, pp. 1783-1789
-
-
Hoarau, D.1
Delmas, P.2
David, S.3
Roux, E.4
Leroux, J.C.5
-
39
-
-
70350728656
-
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
-
Morille M, Montier T, Legras P et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials 31(2), 321-329 (2010).
-
(2010)
Biomaterials
, vol.31
, Issue.2
, pp. 321-329
-
-
Morille, M.1
Montier, T.2
Legras, P.3
-
40
-
-
84866484085
-
Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-beta-cyclodextrin as an oral delivery system
-
Baek JS, So JW, Shin SC, Cho CW. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-beta-cyclodextrin as an oral delivery system. Int. J. Mol. Med. 30(4), 953-959 (2012).
-
(2012)
Int. J. Mol. Med.
, vol.30
, Issue.4
, pp. 953-959
-
-
Baek, J.S.1
So, J.W.2
Shin, S.C.3
Cho, C.W.4
-
41
-
-
45549094992
-
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients
-
Chu Z, Chen J-S, Liau C-T et al. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 19(3), 275-281 (2008).
-
(2008)
Anticancer Drugs
, vol.19
, Issue.3
, pp. 275-281
-
-
Chu, Z.1
Chen, J.-S.2
Liau, C.-T.3
-
42
-
-
84904267805
-
Development of 2D and 3D mucus models and their interactions with mucus penetrating paclitaxel loaded lipid nanocapsules
-
Groo a-C, Mircheva K, Bejaud J et al. Development of 2D and 3D mucus models and their interactions with mucus penetrating paclitaxel loaded lipid nanocapsules. Pharm. Res.31(7), 1753-1765 (2014).
-
(2014)
Pharm. Res.
, vol.31
, Issue.7
, pp. 1753-1765
-
-
Groo, A.-C.1
Mircheva, K.2
Bejaud, J.3
-
43
-
-
0001583660
-
Coadministration of oral cyclosporin a enables oral therapy with paclitaxel
-
Meerum Terwogt JM, Malingré MM, Beijnen JH et al. Coadministration of oral cyclosporin a enables oral therapy with paclitaxel. Clin. Cancer Res. 5(11), 3379-3384 (1999).
-
(1999)
Clin. Cancer Res.
, vol.5
, Issue.11
, pp. 3379-3384
-
-
Meerum Terwogt, J.M.1
Malingré, M.M.2
Beijnen, J.H.3
-
44
-
-
33644922361
-
Effcacy and mechanism of action of chitosan nanocapsules for oral peptide delivery
-
Prego C, Fabre M, Torres D, Alonso MJ. Effcacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm. Res. 23(3), 549-556 (2006).
-
(2006)
Pharm. Res.
, vol.23
, Issue.3
, pp. 549-556
-
-
Prego, C.1
Fabre, M.2
Torres, D.3
Alonso, M.J.4
-
45
-
-
84855435709
-
Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles
-
Siew A, Le H, Thiovolet M, Gellert P, Schatzlein A, Uchegbu I. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol. Pharm. 9(1), 14-28 (2011).
-
(2011)
Mol. Pharm.
, vol.9
, Issue.1
, pp. 14-28
-
-
Siew, A.1
Le Thiovolet H, M.2
Gellert, P.3
Schatzlein, A.4
Uchegbu, I.5
-
46
-
-
79955032379
-
Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles
-
Chakravarthi SS, Robinson DH. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int. J. Pharm. 409(1-2), 111-120 (2011).
-
(2011)
Int. J. Pharm.
, vol.409
, Issue.1-2
, pp. 111-120
-
-
Chakravarthi, S.S.1
Robinson, D.H.2
-
47
-
-
78149342494
-
Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system
-
Li H, Huo M, Zhou J et al. Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. J. Pharm. Sci. 99(11), 4543-4553 (2010).
-
(2010)
J. Pharm. Sci.
, vol.99
, Issue.11
, pp. 4543-4553
-
-
Li, H.1
Huo, M.2
Zhou, J.3
-
48
-
-
79959868168
-
Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus
-
Lai Sk, Suk Js, Pace A et al. Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials 32(26), 6285-6290 (2011).
-
(2011)
Biomaterials
, vol.32
, Issue.26
, pp. 6285-6290
-
-
Sk, L.1
Js, S.2
Pace, A.3
-
49
-
-
57049085726
-
Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier
-
Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew. Chem. Int. Ed. 47(50), 9726-9729 (2008).
-
(2008)
Angew. Chem. Int. Ed.
, vol.47
, Issue.50
, pp. 9726-9729
-
-
Wang, Y.Y.1
Lai, S.K.2
Suk, J.S.3
Pace, A.4
Cone, R.5
Hanes, J.6
-
50
-
-
84857363579
-
A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles
-
Mert O, Lai SK, Ensign L et al. A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. J. Control. Release 157(3), 455-460 (2012).
-
(2012)
J. Control. Release
, vol.157
, Issue.3
, pp. 455-460
-
-
Mert, O.1
Lai, S.K.2
Ensign, L.3
-
51
-
-
84877920679
-
Mucopenetrating nanoparticles: Vehicles for the oral administration of paclitaxel
-
Zabaleta V, Calleja P, Espuelas S et al. Mucopenetrating nanoparticles: vehicles for the oral administration of paclitaxel. Ann. Pharm. Fr. 71(2), 109-118 (2013).
-
(2013)
Ann. Pharm. Fr.
, vol.71
, Issue.2
, pp. 109-118
-
-
Zabaleta, V.1
Calleja, P.2
Espuelas, S.3
-
53
-
-
35448936022
-
Enhancement of cisplatin effcacy by thalidomide in a 9L rat gliosarcoma model
-
Murphy S, Davey RA, Gu XQ et al. Enhancement of cisplatin effcacy by thalidomide in a 9L rat gliosarcoma model. J. Neurooncol. 85(2), 181-189 (2007).
-
(2007)
J. Neurooncol.
, vol.85
, Issue.2
, pp. 181-189
-
-
Murphy, S.1
Davey, R.A.2
Gu, X.Q.3
-
54
-
-
34648831611
-
In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel
-
Lacoeuille F, Hindre F, Moal F et al. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. Int. J. Pharm. 344(1-2), 143-149 (2007).
-
(2007)
Int. J. Pharm.
, vol.344
, Issue.1-2
, pp. 143-149
-
-
Lacoeuille, F.1
Hindre, F.2
Moal, F.3
-
55
-
-
77952491719
-
Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery
-
Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (London) 5(2), 287-306 (2010).
-
(2010)
Nanomedicine (London)
, vol.5
, Issue.2
, pp. 287-306
-
-
Roger, E.1
Lagarce, F.2
Garcion, E.3
Benoit, J.P.4
|